153 related articles for article (PubMed ID: 36266179)
1. Detailed Investigation of Bladder Diary Parameters During Sacral Neuromodulation in Patients With Overactive Symptoms.
Van de Borne S; Tilborghs S; Vaganée D; Vermandel A; De Wachter S
Neuromodulation; 2023 Dec; 26(8):1831-1835. PubMed ID: 36266179
[TBL] [Abstract][Full Text] [Related]
2. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
3. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
4. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
[TBL] [Abstract][Full Text] [Related]
6. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
8. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
9. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
[TBL] [Abstract][Full Text] [Related]
10. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sacral Neuromodulation by Converting Constant Frequency Stimulation Into Variable Frequency Stimulation in Patients With Detrusor Overactivity and Impaired Contractility: A Single-Center Prospective Study.
Zhu W; Shan S; Zhang G; Zhang Q; Zhang J; Che Y; Wen J; Wang Q
Neuromodulation; 2023 Dec; 26(8):1836-1844. PubMed ID: 35977853
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation for detrusor hyperactivity with impaired contractility.
Hennessey DB; Hoag N; Gani J
Neurourol Urodyn; 2017 Nov; 36(8):2117-2122. PubMed ID: 28345779
[TBL] [Abstract][Full Text] [Related]
13. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
[TBL] [Abstract][Full Text] [Related]
14. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
Benson K; McCrery R; Taylor C; Padron O; Blok B; de Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman H; Lane F
Neurourol Urodyn; 2020 Jun; 39(5):1482-1488. PubMed ID: 32339339
[TBL] [Abstract][Full Text] [Related]
15. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
16. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems.
Meng L; Tian Z; Zhang Y; Wang J; Liao L; Chen G; Tian X; Ma L; Li Y; Shi B; Zhang Y; Ling Q; Zhang P; Wei Z; Zhong T; Xu Z; Li J; Luo D
Sci Rep; 2022 Dec; 12(1):22299. PubMed ID: 36566332
[TBL] [Abstract][Full Text] [Related]
18. Effect of pulse width variations on sacral neuromodulation for overactive bladder symptoms: A prospective randomized crossover feasibility study.
Rueb J; Goldman HB; Vasavada S; Moore C; Rackley R; Gill BC
Neurourol Urodyn; 2023 Apr; 42(4):770-777. PubMed ID: 36840886
[TBL] [Abstract][Full Text] [Related]
19. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
[TBL] [Abstract][Full Text] [Related]
20. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
Marinkovic SP; Ford JC
BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
